## MN551

Cat. No.:	HY-156395				
Molecular Formula:	C <sub>26</sub> H <sub>26</sub> ClFN <sub>3</sub> O <sub>7</sub> P				
Molecular Weight:	577.93				
Target:	Others				
Pathway:	Others				
Storage:	Powder	-20°C	3 years		
		4°C	2 years		
	In solvent	-80°C	6 months		
		-20°C	1 month		

## SOLVENT & SOLUBILITY

In Vitro DMSO : 100 m	DMSO : 100 mg/mL (173.03 mM; Need ultrasonic)						
	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg		
		1 mM	1.7303 mL	8.6516 mL	17.3031 mL		
		5 mM	0.3461 mL	1.7303 mL	3.4606 mL		
		10 mM	0.1730 mL	0.8652 mL	1.7303 mL		
	Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (4.33 mM); Clear solution						
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (4.33 mM); Clear solution						
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (4.33 mM); Clear solution						

LOGICAL ACTIV	ТТ
Description	MN551 is a potent inhibitor of cysteine-directed electrophilic covalent that plays important roles in the biology of S its CRL5 complex, and as E3 ligase handles in proteolysis targeting chimera (PROTACs) to induce targeted protein degradation <sup>[1]</sup> .
IC <sub>50</sub> & Target	cysteine-directed electrophilic covalent <sup>[1]</sup>

## REFERENCES

<sup>Q</sup>, он

¥ № NH Ĥ CI



[1]. Sarath Ramachandran, et al. Structure-based design of a phosphotyrosine-masked covalent ligand targeting the E3 ligase SOCS2. Nat Commun. 2023 Oct 10;14(1):6345.

## Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA